Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.1)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 5, May, p. 525–534

doi: 10.17219/acem/118848

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Expressions of miR-122a and miR-3195 in laryngeal cancer and their effects on the proliferation and apoptosis of laryngeal cancer cell Hep-2

Xingli Jiang1,A,B,C,D,E,F, Zhiguang Gao2,A,B,C, Linli Tian1,D,F, Ming Liu1,A,E,F

1 Department of Otorhinolaryngology, and Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, China

2 Department of Otorhinolaryngology, and Head and Neck Surgery, Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology, China

Abstract

Background. Laryngeal cancer (LC) is one of the common malignant tumors in the head and neck area, and the survival rate for patients is low.
Objectives. To investigate miR-122a and miR-3195 expressions in LC tissue, their correlations with clinicopathological features, and their impacts on Hep-2 proliferation and apoptosis.
Material and Methods. Thirty LC and 20 peritumoral tissue specimens were analyzed. miR-122a, miR-122a-negative control sequence, miR-3195, and miR-3195-NG sequence were transfected into Hep-2 in the miR-122a-mimics, miR-122a-NG, miR-3195-mimics, and miR-3195-NG groups, respectively. The miR-122a-mimics-non-transfected and miR-3195-mimics-non-transfected groups used non-transfected Hep-2.
Results. There were lower miR-122a, miR-3195 and occludin protein, and higher TBX1 protein expressions in LC than in the peritumoral tissue; the miR-122a level was associated with clinical stage (all p < 0.001). Positive correlations between miR-122a and miR-3195, and miR-122a and occludin expressions, and a negative correlation between miR-3195 and TBX1 expressions were observed (r = 0.418, r = 0.541, r = −0.428, all p < 0.001). The miR-122a and miR-3195 levels in the 2 mimics groups increased respectively compared to their NG and the non-transfected groups. At different time points after 24 h of transfection, the optical density in the 2 mimics groups was lower than in their NG groups. The miR-122a-mimics group had an increased occludin level and the miR-3195-mimics group had a decreased TBX1 level, and both groups had greater apoptosis rates than their NG groups and in the non-transfected groups (all p < 0.001).
Conclusion. miR-122a is associated with clinical stage. miR-122a and miR-3195 may act as tumor suppressors and play a role in LC pathogenesis. They can suppress Hep-2 proliferation and promote its apoptosis, probably owing to the upregulation of occludin by miR-122a and suppression of TBX1 by miR-3195.

Key words

apoptosis, microRNAs, cell proliferation, laryngeal neoplasms

References (22)

  1. Tomeh C, Holsinger FC. Laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg. 2014;22(2):147–153.
  2. Miao S, Mao X, Zhao S, et al. miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression. Oncotarget. 2017;8(37):62143–62153.
  3. Yu X, Li Z. The role of microRNAs expression in laryngeal cancer. Oncotarget. 2015;6(27):23297–23305.
  4. Nie W, Ge HJ, Yang XQ, et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2016;371(1):99–106.
  5. Fernandez S, Risolino M, Mandia N, et al. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 2015;34(25):3240–3250.
  6. Liu J, Tang Q, Li S, Yang X. Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget. 2016;7(52):86446–86456.
  7. Chen YH, Yu YF. Impact of miR-122a on inhibition proliferation of laryngeal carcinoma cell line Hep2 [in Chinese]. Chinese Journal of Immunology. 2017;33:352–355.
  8. Yoon SO, Kim EK, Lee M, et al. NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal. Oncotarget. 2016;7(3):2475–2495.
  9. Forastiere AA, Ismaila N, Wolf GT. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2018;14:123–128.
  10. Munoz M, Rosso M, Aguilar FJ, Gonzalez-Moles MA, Redondo M, Esteban F. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs. 2008;26(2):111–118.
  11. Wan GL, Chen H, Zhou L, Huang JM. Overexpressed miR-128a inhibits the proliferation of laryngeal cancer cells. Transl Cancer Res. 2018;7(4):901–911.
  12. Wu T, Qu L, He G, et al. Regulation of laryngeal squamous cell cancer progression by the lncRNA H19/miR-148a-3p/DNMT1 axis. Oncotarget. 2016;7(10):11553–11566.
  13. Jin C, Zhang Y, Li J. Upregulation of MiR-196a promotes cell proliferation by downregulating p27(kip1) in laryngeal cancer. Biol Res. 2016;49(1):40.
  14. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently downregulated in human hepatocellular carcinoma. Cancer Res. 2007;67(13):6092–6099.
  15. Zeisel MB, Pfeffer S, Baumert TF. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol. 2013;58(4):821–823.
  16. Lu ZM, Lin YF, Jiang L, et al. Micro-ribonucleic acid expression profiling and bioinformatic target gene analyses in laryngeal carcinoma. Onco Targets Ther. 2014;7:525–533.
  17. Wang X, Lam EK, Zhang J, Jin H, Sung JJ. MicroRNA-122a functions as a novel tumor suppressor downstream of adenomatous polyposis coli in gastrointestinal cancers. Biochem Biophys Res Commun. 2009;387(2):376–380.
  18. Martin TA, Jordan N, Davies EL, Jiang WG. Metastasis to bone in human cancer is associated with loss of occludin expression. Anticancer Res. 2016;36(3):1287–1293.
  19. Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;141(4):1323–1333.
  20. Jingushi K, Kashiwagi Y, Ueda Y, et al. High miR-122 expression promotes malignant phenotypes in ccRCC by targeting occludin. Int J Oncol. 2017;51(1):289–297.
  21. Pane LS, Fulcoli FG, Cirino A, et al. Tbx1 represses Mef2c gene expression and is correlated with histone 3 deacetylation of the anterior heart field enhancer. Dis Model Mech. 2018;11(9). pii: dmm029967. doi:10.1242/dmm.029967
  22. Jiang H, Tian H, Guo Y, et al. Expression of TBX1 gene in kidney tissues in patients with clear cell renal cell carcinoma and its clinical significance. Journal of China Medical University. 2016.
© Wroclaw Medical University